• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Lumen Technologies And 3 Other Stocks Under $3 Insiders Are Buying

    2/28/24 7:21:26 AM ET
    $BCOV
    $CYAN
    $LUMN
    $RZLT
    EDP Services
    Technology
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $BCOV alert in real time by email

    The Dow Jones index closed lower by around 100 points on Tuesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.

    Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga's insider transactions platform.

    Brightcove

    • The Trade: Brightcove Inc. (NASDAQ:BCOV) 10% owner Jonathan Brolin acquired a total of 41,747 shares an average price of $1.86. To acquire these shares, it cost around $77,667. The company’s CEO also bought 25,000 shares of the company.
    • What’s Happening: On Feb. 22, Brightcove reported fourth-quarter financial results and issued FY24 guidance below estimates..
    • What Brightcove Does: Brightcove Inc is a provider of cloud-based streaming technology and services.

    Lumen Technologies

    • The Trade: Lumen Technologies, Inc. (NYSE:LUMN) Director T Michael Glenn acquired a total of 50,000 shares at at an average price of $1.47. To acquire these shares, it cost around $73,300.
    • What’s Happening: On Feb. 6, Lumen Technologies reported better-than-expected fourth-quarter financial results.
    • What Lumen Technologies Does: With 450,000 route miles of fiber, Lumen Technologies is one of the United States' largest telecommunications carriers serving global enterprises.

    Check This Out: Macy's, Lowe's And 3 Stocks To Watch Heading Into Tuesday

    Rezolute

    • The Trade: Rezolute, Inc. (NASDAQ:RZLT) Chief Medical Officer Brian Kenneth Roberts acquired a total of 8,000 shares at an average price of $1.69. The insider spent around $13,540 to buy those shares.
    • What’s Happening: On Feb. 13, Rezolute posted a narrower-than-expected second-quarter loss.
    • What Rezolute Does: Rezolute Inc is a biopharmaceutical company. The company develops novel, sustained-release injectable therapies.

    Cyanotech

    • The Trade: Cyanotech Corporation (OTC:CYAN) VP, Operations Glenn Jensen acquired a total of 16,835 shares at an average price of $0.31. The insider spent around $5,222 to buy those shares.
    • What’s Happening: On Feb. 8, Cyanotech posted a wider quarterly loss.
    • What Cyanotech Does: Cyanotech Corp is engaged in the production of natural products derived from microalgae for the nutritional supplements market.


    Don’t forget to check out our premarket coverage here

    Get the next $BCOV alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BCOV
    $CYAN
    $LUMN
    $RZLT

    CompanyDatePrice TargetRatingAnalyst
    Lumen Technologies Inc.
    $LUMN
    2/4/2026Outperform → Mkt Perform
    Raymond James
    Rezolute Inc.
    $RZLT
    12/11/2025$2.00Buy → Hold
    Craig Hallum
    Rezolute Inc.
    $RZLT
    12/11/2025Overweight → Neutral
    Cantor Fitzgerald
    Rezolute Inc.
    $RZLT
    12/11/2025$1.00Outperform → Neutral
    Wedbush
    Lumen Technologies Inc.
    $LUMN
    10/31/2025$11.00Buy → Neutral
    Citigroup
    Lumen Technologies Inc.
    $LUMN
    9/2/2025$4.09Neutral
    Goldman
    Lumen Technologies Inc.
    $LUMN
    5/5/2025$4.50Mkt Perform → Outperform
    Raymond James
    Lumen Technologies Inc.
    $LUMN
    2/26/2025$8.00 → $6.50Neutral → Buy
    Citigroup
    More analyst ratings

    $BCOV
    $CYAN
    $LUMN
    $RZLT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Linear Diankha sold $355,050 worth of shares (45,000 units at $7.89), decreasing direct ownership by 19% to 198,229 units (SEC Form 4)

    4 - Lumen Technologies, Inc. (0000018926) (Issuer)

    2/20/26 7:09:04 PM ET
    $LUMN
    Telecommunications Equipment
    Telecommunications

    EVP, Chief Revenue Officer Sharritts Jeffery S. was granted 576,282 shares (SEC Form 4)

    4 - Lumen Technologies, Inc. (0000018926) (Issuer)

    2/6/26 5:35:03 PM ET
    $LUMN
    Telecommunications Equipment
    Telecommunications

    SEC Form 3 filed by new insider Sharritts Jeffery S.

    3 - Lumen Technologies, Inc. (0000018926) (Issuer)

    2/6/26 5:33:18 PM ET
    $LUMN
    Telecommunications Equipment
    Telecommunications

    $BCOV
    $CYAN
    $LUMN
    $RZLT
    SEC Filings

    View All

    SEC Form 10-K filed by Lumen Technologies Inc.

    10-K - Lumen Technologies, Inc. (0000018926) (Filer)

    2/20/26 4:18:31 PM ET
    $LUMN
    Telecommunications Equipment
    Telecommunications

    SEC Form 15-12G filed by Cyanotech Corporation

    15-12G - CYANOTECH CORP (0000768408) (Filer)

    2/13/26 2:42:59 PM ET
    $CYAN
    Medicinal Chemicals and Botanical Products
    Health Care

    Amendment: SEC Form SC 13E3/A filed by Cyanotech Corporation

    SC 13E3/A - CYANOTECH CORP (0000768408) (Subject)

    2/13/26 2:09:31 PM ET
    $CYAN
    Medicinal Chemicals and Botanical Products
    Health Care

    $BCOV
    $CYAN
    $LUMN
    $RZLT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Lumen Boosts AI Network Transformation with Blue Planet's AI Studio and Agents

    Blue Planet AI agents to help automate Lumen's network operations Initial use cases include device model generation and digital network twin applications AI agents support Lumen's success in building an AI-ready network Blue Planet, a division of Ciena (NYSE:CIEN), today announced that Lumen Technologies (NYSE:LUMN) is adopting the company's AI agents across its network operations to help enhance efficiency and deliver exceptional customer experiences. As part of its strategy to build the trusted network for AI, Lumen will use Blue Planet AI Studio, an operations support system (OSS)-native platform, to build, manage, and run AI agents across multiple network domains to drive fast

    2/19/26 9:00:00 AM ET
    $CIEN
    $LUMN
    Telecommunications Equipment
    Utilities
    Telecommunications

    Lumen to Host Investor Day on Feb. 25, 2026

    As previously announced, Lumen Technologies (NYSE: LUMN) will host an Investor Day on Wednesday, Feb. 25, 2026. Presentations will begin at approximately 8:30 a.m. ET and conclude around 12 p.m. ET. During the program, Lumen's senior leadership team will outline the company's next phase of transformation, including its commercial engine, product pipeline, financial framework, and multi-year growth strategy designed to strengthen earnings power and long-term value creation. The live webcast and post-event replay will be accessible on Lumen's Investor Relations website under Investor Day. The replay and summary materials from the presentations will be available on the website approximatel

    2/18/26 6:55:00 AM ET
    $LUMN
    Telecommunications Equipment
    Telecommunications

    QVC Group, Inc. Announces Semi-Annual Interest Payment and Regular Additional Distribution on 3.75% Senior Exchangeable Debentures Due 2030

    WEST CHESTER, Pa., Feb. 17, 2026 /PRNewswire/ -- QVC Group, Inc. ("QVC Group") (NASDAQ:QVCGA, QVCGP, OTCQB:QVCGB) today announced the payment of a semi-annual interest payment and Regular Additional Distribution to the holders as of February 1, 2026 of the 3.75% Senior Exchangeable Debentures due 2030 (the "Debentures") issued by its wholly-owned subsidiary, Liberty Interactive LLC ("LI LLC"). The semi-annual interest payment amount is $18.75 per $1,000 original principal amount of Debentures, and the amount of the Regular Additional Distribution is $0.4596 per $1,000 original principal amount of Debentures.

    2/17/26 4:01:00 PM ET
    $LUMN
    $QVCGA
    $QVCGB
    Telecommunications Equipment
    Telecommunications
    Catalog/Specialty Distribution
    Consumer Discretionary

    $BCOV
    $CYAN
    $LUMN
    $RZLT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President & CEO Johnson Kathleen E bought $499,925 worth of shares (78,685 units at $6.35), increasing direct ownership by 0.93% to 8,562,582 units (SEC Form 4)

    4 - Lumen Technologies, Inc. (0000018926) (Issuer)

    2/5/26 5:34:09 PM ET
    $LUMN
    Telecommunications Equipment
    Telecommunications

    Director Hogenhuis Wladimir bought $9,548 worth of shares (5,650 units at $1.69), increasing direct ownership by 5% to 119,675 units (SEC Form 4)

    4 - Rezolute, Inc. (0001509261) (Issuer)

    12/17/25 4:14:55 PM ET
    $RZLT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Medical Officer Roberts Brian Kenneth bought $47,600 worth of shares (28,000 units at $1.70), increasing direct ownership by 10% to 308,352 units (SEC Form 4)

    4 - Rezolute, Inc. (0001509261) (Issuer)

    12/17/25 4:13:53 PM ET
    $RZLT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BCOV
    $CYAN
    $LUMN
    $RZLT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Lumen Technologies downgraded by Raymond James

    Raymond James downgraded Lumen Technologies from Outperform to Mkt Perform

    2/4/26 8:28:23 AM ET
    $LUMN
    Telecommunications Equipment
    Telecommunications

    Rezolute downgraded by Craig Hallum with a new price target

    Craig Hallum downgraded Rezolute from Buy to Hold and set a new price target of $2.00

    12/11/25 3:51:30 PM ET
    $RZLT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Rezolute downgraded by Cantor Fitzgerald

    Cantor Fitzgerald downgraded Rezolute from Overweight to Neutral

    12/11/25 12:30:42 PM ET
    $RZLT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BCOV
    $CYAN
    $LUMN
    $RZLT
    Financials

    Live finance-specific insights

    View All

    QVC Group, Inc. Announces Semi-Annual Interest Payment and Regular Additional Distribution on 3.75% Senior Exchangeable Debentures Due 2030

    WEST CHESTER, Pa., Feb. 17, 2026 /PRNewswire/ -- QVC Group, Inc. ("QVC Group") (NASDAQ:QVCGA, QVCGP, OTCQB:QVCGB) today announced the payment of a semi-annual interest payment and Regular Additional Distribution to the holders as of February 1, 2026 of the 3.75% Senior Exchangeable Debentures due 2030 (the "Debentures") issued by its wholly-owned subsidiary, Liberty Interactive LLC ("LI LLC"). The semi-annual interest payment amount is $18.75 per $1,000 original principal amount of Debentures, and the amount of the Regular Additional Distribution is $0.4596 per $1,000 original principal amount of Debentures.

    2/17/26 4:01:00 PM ET
    $LUMN
    $QVCGA
    $QVCGB
    Telecommunications Equipment
    Telecommunications
    Catalog/Specialty Distribution
    Consumer Discretionary

    Lumen Technologies Reports Solid Fourth Quarter and Full Year 2025 Results; Completes AT&T Transaction, Strengthening Balance Sheet and Advancing Enterprise Focus

    Delivers revenue, Adjusted EBITDA and free cash flow in line with expectations as Lumen sharpens focus on high-value enterprise growth Signs additional $2.5B in PCF contracts and grows NaaS customer base, showing continued momentum on company's return to growth Lumen Technologies (NYSE:LUMN) reported results for the fourth quarter and full year ended Dec. 31, 2025. AT&T Transaction Closes: Completed the $5.75 billion transaction with AT&T, reducing total debt by over $4.8 billion and net leverage by a full turn to below 4x. Annual interest expense is down nearly 45% vs. 2025 levels, and capex is reduced by over $1 billion, increasing flexibility to invest in network modernization and

    2/3/26 4:01:00 PM ET
    $LUMN
    Telecommunications Equipment
    Telecommunications

    Lumen Completes Sale of Consumer Fiber-to-the-Home Business to AT&T

    Transaction Close Marks Strategic Inflection Point; Positions Lumen as a Pure Play Enterprise-Focused Technology Infrastructure Company on Path to Sustainable Growth Lumen Technologies (NYSE: LUMN) today announced that it has completed the sale of its Mass Markets fiber-to-the-home business in eleven states, including Quantum Fiber, to AT&T (NYSE: T) for $5.75 billion in cash. The sale includes substantially all of the related consumer fiber access network and customer relationships in those states, which serves more than 1 million fiber customers and reaches more than 4 million enabled fiber locations. The completed transaction is another strategic milestone in Lumen's transformation int

    2/2/26 6:35:00 AM ET
    $LUMN
    $T
    Telecommunications Equipment
    Telecommunications

    $BCOV
    $CYAN
    $LUMN
    $RZLT
    Leadership Updates

    Live Leadership Updates

    View All

    Lumen Technologies Appoints Jeff Sharritts as Chief Revenue Officer

    Veteran leader to deepen customer relationships, sharpen execution, and scale company's commercial engine in Lumen's next phase of transformation Lumen Technologies (NYSE: LUMN) today announced that Jeff Sharritts has been appointed Executive Vice President and Chief Revenue Officer, effective Feb. 4, 2026. He will report to Lumen CEO Kate Johnson and will lead Lumen's commercial strategy, including the Acceleration and Growth Team, with a focus on deepening customer relationships and driving profitable growth for the company. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260203640994/en/LUMN) as EVP and Chief Revenue Officer

    2/3/26 4:01:00 PM ET
    $LUMN
    Telecommunications Equipment
    Telecommunications

    Lumen Appoints Jim Fowler as Chief Technology & Product Officer

    Lumen Technologies (NYSE: LUMN) today announced that Jim Fowler has been appointed Executive Vice President and Chief Technology & Product Officer, effective Jan. 5, 2026. Fowler will succeed Dave Ward, who is departing to assume the role of President and Chief Architect at Salesforce, the world's #1 AI CRM. Ward will remain with Lumen through Jan. 23, 2026, to support a smooth transition. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205883387/en/Jim Fowler, who will assume the role of Executive Vice President and Chief Technology & Product Officer at Lumen Technologies, effective Jan. 5, 2026. Source: Lumen Technologies Fow

    12/5/25 8:30:00 AM ET
    $LUMN
    Telecommunications Equipment
    Telecommunications

    Rezolute Appoints Seasoned Commercial Executive Sunil Karnawat as Chief Commercial Officer

    REDWOOD CITY, Calif., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Rezolute, Inc. (NASDAQ:RZLT) ("Rezolute" or the "Company"), a late-stage rare disease company focused on treating hypoglycemia caused by hyperinsulinism (HI), today announced the appointment of Sunil Karnawat as Chief Commercial Officer, effective August 18, 2025. "We're thrilled to welcome Sunil to our leadership team at such a pivotal point as we advance ersodetug through Phase 3 studies for both congenital and tumor hyperinsulinism," said Nevan Charles Elam, Chief Executive Officer and Founder of Rezolute. "His proven track record of successfully bringing therapies to patients across multiple therapeutic areas, including four ultr

    8/20/25 7:30:00 AM ET
    $RZLT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BCOV
    $CYAN
    $LUMN
    $RZLT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Brightcove Inc.

    SC 13G - BRIGHTCOVE INC (0001313275) (Subject)

    12/3/24 5:05:52 PM ET
    $BCOV
    EDP Services
    Technology

    Amendment: SEC Form SC 13G/A filed by Rezolute Inc.

    SC 13G/A - Rezolute, Inc. (0001509261) (Subject)

    11/14/24 6:59:50 PM ET
    $RZLT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Rezolute Inc.

    SC 13G/A - Rezolute, Inc. (0001509261) (Subject)

    11/14/24 10:04:23 AM ET
    $RZLT
    Biotechnology: Pharmaceutical Preparations
    Health Care